Standard and novel therapeutic approaches to Behçet's disease

Drugs

Volumn 67, Issue 14, 2007, Pages 2013-2022

  Gul, Ahmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Azathioprine, therapeutic use; Behcet's syndrome, treatment; Benzathine benzylpenicillin, therapeutic use; Ciclosporin, therapeutic use; Colchicine, therapeutic use; Dapsone, therapeutic use; Etanercept, therapeutic use; Infliximab, therapeutic use

Indexed keywords

ACICLOVIR; ALPHA2A INTERFERON; ALPHA2C INTERFERON; AZAPROPAZONE; AZATHIOPRINE; BENZATHINE PENICILLIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; PLACEBO; REBAMIPIDE; SUCRALFATE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE;

BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; EYE INJURY; GENITAL ULCER; HEALTH SURVEY; HUMAN; MONOTHERAPY; MORTALITY; MOUTH ULCER; NONHUMAN; PATIENT SATISFACTION; PROGNOSIS; PROPHYLAXIS; PULMONARY ARTERY ANEURYSM; RELAPSE; RETINA MACULA CYSTOID EDEMA; REVIEW; SKIN DEFECT; UVEITIS;

EID: 34948817757     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767140-00004     Document Type: Review

References (53)

1. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med 1999 Oct 21; 341 (17): 1284-91
2. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 Jan; 82 (1): 60-76
3. Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984 Dec; 43 (6): 783-9
4. Gul A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Behçet's disease. Rheumatology (Oxford) 2001 Jun; 40 (6): 668-72
5. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001 Sep-Oct; 19 (5 Suppl. 24): S6-12
6. Gul A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005 Feb; 4 (1): 81-3
7. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990 May 5; 335 (8697): 1078-80
8. The International Study Group for Behçet's disease. Evaluation of diagnostic ('classification') criteria in Behçet's disease: towards internationally agreed criteria. Br J Rheumatol 1992 May; 31 (5): 299-308
9. Akman-Demir G, Baykan-Kurt B, Serdaroglu P, et al. Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch Neurol 1996 Jul; 53 (7): 691-4
10. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004 Sep; 138 (3): 373-80
11. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004 Dec 1; 117 (11): 867-70
12. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997 Apr; 40 (4): 769-74
13. Saenz A, Ausejo M, Shea B, et al. Pharmacotherapy for Behçet's syndrome. Cochrane Database Syst Rev 2000; (2): CD001084
14. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001 Nov; 44 (11): 2686-92
15. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005 Aug; 52 (8): 2478-84
16. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 Jul; 31 (7): 1362-8
17. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease. J Rheumatol 2004 Jul; 31 (7): 1241-3
18. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990 Feb 1; 322 (5): 281-5
19. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989 May 20; I (8647): 1093-6
20. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980 Jun; 65 (3): 399-402
21. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 Mar 15; 128 (6): 443-50
22. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002 May; 29 (5): 267-79
23. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006 Mar; 45 (3): 348-52
24. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Br J Rheumatol 1988 Aug; 27 (4): 300-2
25. Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995 Jul-Aug; 13 (4): 493-5
26. Calguneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease: a randomized clinical trial. Arthritis Rheum 1996 Dec; 39 (12): 2062-5
27. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003; 4 (1): 19-28
28. Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspen-sion in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999 May; 135 (5): 529-32
29. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002 Apr; 138 (4): 467-71
30. Hamuryudan V, Yurdakul S, Rosenkaimer F, et al. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial. Br J Rheumatol 1991 Oct; 30 (5): 395-6
31. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005 Jan; 32 (1): 98-105
32. Barnes CG. Treatment of Behçet's syndrome. Rheumatology (Oxford) 2006 Mar; 45 (3): 245-7
33. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006; 46 (2): 141-64
34. Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001 May; 131 (5): 679
35. Karacorlu M, Mudun B, Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol 2004 Aug; 138 (2): 289-91
36. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991 Aug 15; 112 (2): 138-46
37. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 Apr; 87 (4): 423-31
38. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001 Jul 28; 358 (9278): 295-6
39. Erkan F, Gul A, Tasali E. Pulmonary manifestations of Behçet's disease. Thorax 2001 Jul; 56 (7): 572-8
40. Yazici H, Yurdakul S, Hamuryudan V. The management of Behçet's syndrome: how are we doing? Clin Exp Rheumatol 1999 Mar-Apr; 17 (2): 145-7
41. Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 2003 Sep; 60 (9): 1903-22
42. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol 2006 May-Jun; 50 (3): 256-65
43. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm 2001 Dec; 9 (4): 219-29
44. Mamo JG. Treatment of Behçet disease with chlorambucil: a follow-up report. Arch Ophthalmol 1976 Apr; 94 (4): 580-3
45. Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease: Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 1991 Dec; 23 (6): 3343-6
46. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. Epub 2006 May 4
47. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004 Mar 2; 140 (5): 404-6
48. Pervin K, Childerstone A, Shinnick T, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet's disease. J Immunol 1993 Aug 15; 151 (4): 2273-82
49. Hasan A, Fortune F, Wilson A, et al. Role of gamma delta T cells in pathogenesis and diagnosis of Behçet's disease. Lancet 1996 Mar 23; 347 (9004): 789-94
50. Phipps PA, Stanford MR, Sun J-B, et al. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 2003; 33: 224-32
51. Stanford M, Whittall T, Bergmeier LA, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behçet's disease. Clin Exp Immunol 2004 Jul; 137 (1): 201-8
52. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999 Mar; 106 (3): 586-9
53. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999 May; 246 (5): 339-46